An all new vaccine has been put against meningitis B that apparently will be scheduled for the next year with Novartis claiming that the shot has been tested in case of human beings.

Novartis’ drug, Bexsero has been bestowed by health experts who state that the jab will aid in a sharp decline in the number of children death due to the disease.

According to Novartis, the medicine has been proven positive in trials in which more than 7,500 children, adolescents and adults were a part of the drug trials that releases antibodies against more than 77 percent of more than 800 meningitis B strains.

According to Andrin Oswald, Head of Novartis Vaccines and Diagnostics Division, “The Bexsero submission in the EU is an important milestone toward achieving the world's first broad-coverage MenB vaccine through our unique multi-component approach.”

Steve Dayman, chief executive of the Meningitis UK charity, whose son Spencer died because of the disease in 1982, explained which comprised of the most vital shots that evolved since polio vaccination took off in the 1960s.